Skip to main content

Sentynl Cares | NULIBRY Access and Support program is committed to providing affordability options for NULIBRY

Sentynl Cares | NULIBRY offers financial assistance options for your patients and their parents or caregivers

Benefits Verification

Sentynl Cares | NULIBRY will automatically conduct an insurance benefits verification for all NULIBRY families.

  • Determine insurance status
  • Communicate copay responsibility to the parent/caregiver

Sentynl Cares | NULIBRY Acute Site QuickStart Program

The Sentynl Cares | NULIBRY Acute Site QuickStart Program may help patients who are initially prescribed NULIBRY. Click the link below for more information on the NULIBRY Acute Site QuickStart Program.

Sentynl Cares | NULIBRY Copay Assistance Program

Provides eligible commercially insured patients assistance with copay and coinsurance costs.*

Sentynl Cares | NULIBRY Patient Assistance Program (PAP)

Sentynl Cares | NULIBRY provides support for patients who are uninsured or underinsured and meet certain financial qualifications. Patients may qualify for free NULIBRY medication.

Help your patients access the Sentynl Cares | NULIBRY PAP

Download Form
Sentynl Cares access support program logo

Sentynl Cares | NULIBRY
Access and Support

For questions or additional info, give us a call. Our support team is ready to help.

If you have a suspected or confirmed patient with MoCD Type A, please call Sentynl Cares at
1-888-251-2800

*The Program will not be available for any Patient who is a beneficiary of, or if any part of the prescription is covered or reimbursed by any federal or state healthcare program (Medicare, Medicaid, TRICARE, Veterans Administration, Department of Defense, etc.), including a state or territory pharmaceutical assistance program; or The Medicare Prescription Drug Program (Part D), or if the Patient is currently in the coverage gap, Medicare Advantage Plans, Medicaid Managed Care or Alternative Benefit Plans under the Affordable Care Act, or Medigap.

Forms & Other Resources >

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Potential for Photosensitivity

NULIBRY can make the patient oversensitive to sunlight. NULIBRY-treated patients or their caregivers are advised to avoid or minimize patient exposure to sunlight and artificial UV light and adopt precautionary measures when exposed to the sun, including wearing protective clothing and sunglasses, and use broad-spectrum sunscreen with high SPF in patients 6 months of age and older. If photosensitivity occurs, caregivers/patients are advised to seek medical attention immediately and consider a dermatological evaluation.

SIDE EFFECTS

The most common side effects in NULIBRY-treated patients were infusion catheter–related complications, pyrexia (fever), viral infection, pneumonia, otitis media (ear infection), vomiting, cough/sneezing, viral upper respiratory infection (common cold/flu-like infection), gastroenteritis (stomach flu-like symptoms), diarrhea, and bacteremia (bacteria in the blood). Side effects for rcPMP-treated patients were similar to the NULIBRY-treated patients.

PATIENT COUNSELING INFORMATION

Please read the FDA-approved NULIBRY Prescribing Information and Instructions for Use and follow the instructions on how to prepare and administer NULIBRY.

NULIBRY has a potential for photosensitivity; see Warnings and Precautions. Seek medical attention immediately if the patient develops a rash or if they notice symptoms of photosensitivity reactions (redness, burning sensation of the skin, blisters).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information for NULIBRY.